Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management
Nutrients · 2024
DOI: 10.3390/nu16162781 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2024. Verfasst von Giovanna Gallo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy. Hauptthemen laut MEDLINE: Obesity, Cardiovascular Diseases, Heart Disease Risk Factors. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is an epidemic worldwide. Overweight and multiple obesity-related mechanisms, including dysmetabolic alterations, contribute to cardiovascular deleterious effects. Hence, overweight and obesity have been independently associated with increased cardiovascular risk, whose assessment is crucial for preserving life quality and reducing mortality, and to address appropriate therapeutic strategies in obese patients. Beyond the standard of care in managing overweight and obesity in adults (i.e., diet and physical exercise), several relevant pharmacotherapies have been approved, and several procedures and device types for weight loss have been recommended. In such a contest, medical weight management remains one option for treating excess weight. Most drugs used for obesity reduce appetite and increase satiety and, secondarily, slow gastric emptying to reduce body weight and, therefore, act also to improve metabolic parameters. In this contest, agonists of the glucagon-like peptide-1 receptor (GLP-1RAs) modulate different metabolic pathways associated with glucose metabolism, energy homeostasis, antioxidation, and inflammation. Moreover, this class of drugs has shown efficacy in improving glycemic control, reducing the incidence of cardiovascular events in type 2 diabetic patients, and reducing body weight independently of the presence of diabetes. Recently, in overweight or obese patients with pre-existing cardiovascular disease but without diabetes, the GLP-1RA semaglutide reduced the incidence of cardiovascular and cerebrovascular events and death from cardiovascular causes. Thus, semaglutide has been approved for secondary prevention in obese people with cardiovascular disease. Nevertheless, whether this class of drugs is equally effective for primary prevention in obese people has to be demonstrated. In this review, we will summarize updates on the pathophysiology of obesity, the effects of obesity on cardiovascular risk, the impact of different obesity phenotypes on cardiovascular diseases, and the novelties in the clinical management of obesity for cardiovascular prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy.
- Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
ORCID-Profile: Giovanna Gallo, Giovambattista Desideri, Carmine Savoia
Zitieren
APA
Gallo, G., Desideri, G., & Savoia, C. (2024). Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management. Nutrients. https://doi.org/10.3390/nu16162781
Vancouver
Gallo G, Desideri G, Savoia C. Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management. Nutrients. 2024. doi:10.3390/nu16162781
BibTeX
@article{Gallo2024,
author = {Gallo, Giovanna and Desideri, Giovambattista and Savoia, Carmine},
title = {Update on Obesity and Cardiovascular Risk: From Pathophysiology to Clinical Management},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16162781}
}
EUVIMED